Your browser doesn't support javascript.
loading
Recombinant Bet v 1-BanLec chimera modulates functional characteristics of peritoneal murine macrophages by promoting IL-10 secretion.
Protic-Rosic, Isidora; Nesic, Andrijana; Lukic, Ivana; Miljkovic, Radmila; Popovic, Dragan M; Atanaskovic-Markovic, Marina; Stojanovic, Marijana; Gavrovic-Jankulovic, Marija.
Afiliación
  • Protic-Rosic I; Department of Biochemistry, Faculty of Chemistry University of Belgrade, Belgrade, Serbia.
  • Nesic A; Department of Biochemistry, Faculty of Chemistry University of Belgrade, Belgrade, Serbia.
  • Lukic I; Department of Research and Development, Institute of Virology, Vaccines and Sera, Torlak, Belgrade, Serbia.
  • Miljkovic R; Department of Research and Development, Institute of Virology, Vaccines and Sera, Torlak, Belgrade, Serbia.
  • Popovic DM; University of Belgrade - Institute of Chemistry, Technology and Metallurgy - National Institute of the Republic of Serbia, Belgrade, Serbia.
  • Atanaskovic-Markovic M; Department of Allergology and Pulmonology, University Children's Hospital, Medical Faculty University of Belgrade, Belgrade, Serbia.
  • Stojanovic M; Department of Research and Development, Institute of Virology, Vaccines and Sera, Torlak, Belgrade, Serbia.
  • Gavrovic-Jankulovic M; Department of Biochemistry, Faculty of Chemistry University of Belgrade, Belgrade, Serbia. Electronic address: mgavrov@chem.bg.ac.rs.
Mol Immunol ; 138: 58-67, 2021 10.
Article en En | MEDLINE | ID: mdl-34364073
Allergen-specific immunotherapy (AIT) is a desensitizing treatment for allergic diseases that corrects the underlined pathological immune response to innocuous protein antigens, called allergens. Recombinant allergens employed in the AIT allowed the production of well-defined formulations that possessed consistent quality but were often less efficient than natural allergen extracts. Combining recombinant allergens with an adjuvant or immunomodulatory agent could improve AIT efficacy. This study aimed to perform structural and functional characterization of newly designed recombinant chimera composed of the Bet v 1, the major birch pollen allergen, and Banana Lectin (BanLec), TLR2, and CD14 binding protein, for the application in AIT. rBet v 1-BanLec chimera was designed in silico and expressed as a soluble fraction in Escherichia coli. Purified rBet v 1-BanLec (33.4 kDa) retained BanLec-associated biological activity of carbohydrate-binding and preserved IgE reactive epitopes of Bet v 1. The chimera revealed secondary structures with predominant ß sheets. The immunomodulatory capacity of rBet v 1-BanLec tested on macrophages showed changes in myeloperoxidase activity, reduced NO production, and significant alterations in the production of cytokines when compared to both rBanLec and rBet v 1. Comparing to rBet v 1, rBet v 1-BanLec was demonstrated to be more efficient promoter of IL-10 production as well as weaker inducer of NO production and secretion of pro-inflammatory cytokines TNFα, and IL-6. The ability of rBet v 1-BanLec to promote IL-10 in together with the preserved 3D structure of Bet v 1 part implies that the construct might exert a beneficial effect in the allergen-specific immunotherapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Desensibilización Inmunológica / Interleucina-10 / Macrófagos Peritoneales / Musa / Lectinas de Plantas / Antígenos de Plantas Límite: Animals Idioma: En Revista: Mol Immunol Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Desensibilización Inmunológica / Interleucina-10 / Macrófagos Peritoneales / Musa / Lectinas de Plantas / Antígenos de Plantas Límite: Animals Idioma: En Revista: Mol Immunol Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido